Survey findings suggest that cluster headache attacks can negatively affect an individual’s career, education, and social life.
As a result of the vote, Nektar has decided to withdraw the New Drug Application for oxycodegol and to cease further development of the product.
Acute treatment of migraine with ubrogepant, an oral calcitonin gene-related peptide antagonist, was superior to placebo for migraine pain freedom.
Larger contralateral trigeminal nerve and hippocampus volumes are predictive of early nonresponse to surgical treatment of trigeminal neuralgia.
Spinal cord stimulation (SCS) with a closed-loop system that uses recorded evoked compound action potentials (ECAPs) is superior to a fixed-output, open-loop system for patients with chronic back and leg pain.
Researchers found the use of acupuncture and/or acupressure is associated with reduced cancer pain and decreased use of analgesics.
The newly developed Migraine Aura Complexity Score is effective for stratifying patients with migraine with aura.
Researchers found that a poor night’s sleep may increase risk for migraine the following day, rather than the next morning.
The Food and Drug Administration (FDA) has approved Ubrelvy (ubrogepant tablets; Allergan), the first oral calcitonin gene-related peptide (CGRP) receptor antagonist, for the acute treatment of migraine with or without aura in adults.
Evidence supports the use of high-dose aspirin for treating acute migraine and low-dose aspirin for prevention of recurrent attacks.